A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting

You may be eligible if

• Enrolled in the CorEvitas RA Registry and initiated tofacitinib on or after November 2012.
• Initiate tofacitinib (defined as first ever use of tofacitinib) at Registry enrollment visit or at a Registry follow-up visit after November 2012
• Have prior use of rituximab
• Have CDAI measured at baseline and appropriate follow-up visit.